The number of pharmaceutical companies based in Baden-Württemberg that conduct research, development and/or production currently totals 90 companies. In 2023, these companies achieved a taxable turnover of 8.24 billion euros and employed a total of 25,074 persons. Regionally, most pharmaceutical companies are located in the areas of Freiburg/Offenburg/Lörrach (14 companies), Karlsruhe (13 companies) and Stuttgart (14 companies). However, the economically strongest regions are the Hochrhein-Bodensee area and the Donau-Iller region around Ulm and Biberach, which generate the highest revenue.

Baden-Württemberg benefits from an excellent research landscape with internationally acknowledged universities and research institutions that work closely with the industry. The pharmaceutical industry invests around 16 percent of its revenue in research and development, making it the industry sector with the highest amount of internal R&D expenditure.¹⁾ This high level of willingness to innovate plays a key role in ensuring that the region remains competitive on an international level.

The product portfolio of Baden-Württemberg's pharmaceutical companies reaches from innovative medicines and generics to herbal and homeopathic preparations. It is particularly noteworthy that more than 22 percent of the companies also produce phytopharmaceuticals. Many manufacturers focus on sustainable modes of action - whether ecological, for example through their own medicinal plant gardens and co-operation with organic cultivation projects, or social, through a wide range of social engagement.

Biotechnology is a key driver of innovation for the pharmaceutical industry. In Baden-Württemberg, a total of 276 companies are active in the biotechnology and/or pharmaceutical industry and carry out research, development or production at the location. In 2022, these companies generated a taxable revenue of 10.02 billion euros with 39,957 employees - impressive proof of the state's economic strength and innovative power.